Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial by Younossi ZM et al.
1 
 
Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis— 
Interim Analysis From a Multicentre, Randomised, Placebo-Controlled Phase 3 Study 
 
Zobair M. Younossi*, Vlad Ratziu*, Rohit Loomba, Mary Rinella, Quentin M. Anstee, Zachary Goodman, Pierre 
Bedossa, Andreas Geier, Susanne Beckebaum, Philip N. Newsome, David Sheridan, Muhammad Y. Sheikh, James 
Trotter, Whitfield Knapple, Eric Lawitz, Manal F. Abdelmalek, Kris V. Kowdley, Aldo J. Montano-Loza, Jerome 
Boursier, Philippe Mathurin, Elisabetta Bugianesi, Giuseppe Mazzella, Antonio Olveira, Helena Cortez-Pinto, Isabel 
Graupera, David Orr, Lise Lotte Gluud, Jean-Francois Dufour, David Shapiro, Jason Campagna, Luna Zaru, Leigh 
MacConell, Reshma Shringarpure, Stephen Harrison†, Arun J. Sanyal†, on behalf of the REGENERATE Study 
Investigators 
 
 
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA (Z M 
Younossi MD, Z Goodman MD); Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié – 
Salpêtrière, Institute for Cardiometabolism and Nutrition, Paris, France (V Ratziu MD); University of 
California San Diego, San Diego, CA, USA (R Loomba MD); Feinberg School of Medicine, Northwestern 
University, Chicago, IL, USA (M Rinella MD); The Newcastle Liver Research Group, Institute of Cellular 
Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom & 
Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, 
Newcastle Upon Tyne, United Kingdom (Q M Anstee MD); Service d'Anatomie Pathologique, Hôpital 
Beaujon, Assistance Publique-Hôpitaux de Paris, Paris, France (P Bedossa MD); University of Wuerzburg, 
Wuerzburg, Germany (A Geier MD); St. Josef-Krankenhaus Kupferdreh, Essen, Germany (S Beckebaum 
MD); National Institute for Health Research Biomedical Research Centre at University Hospitals 
Birmingham NHS Foundation Trust and the University of Birmingham, UK; Centre for Liver and 
Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, 
Birmingham, United Kingdom (P N Newsome MD); Institute of Translational & Stratified Medicine, 
University of Plymouth & University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom (D Sheridan 
MD); Fresno Clinical Research Center, Fresno, CA, USA (M Y Sheikh MD); Baylor Health, Liver Consultants 
of Texas, Dallas, TX, USA (J Trotter MD); Arkansas Gastroenterology, North Little Rock, AR, USA (W 
Knapple MD); Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA (E 
Lawitz MD); Duke University Medical Center Division of Gastroenterology and Hepatology, Durham, NC, 
USA (M F Abdelmalek MD); Swedish Liver Center, Seattle, WA, USA (Prof K Kowdley MD); Division of 
Gastroenterology and Liver Unit, University of Alberta, Edmonton, Canada (A J Montano-Loza MD); Angers 
University Hospital & Angers University, Angers, France (J Boursier MD, PhD); Hepato-gastroenterology, 
CHU Lille, Lille, France (P Mathurin MD); Department of Medical Sciences, University of Turin, Turin, Italy 
(E Bugianesi MD); University of Bologna, Bologna, Italy (G Mazzella MD); Hospital Universitario La Paz, 
Madrid, Spain (A Oliveira MD); Clínica Universitária de Gastrenterologia, Faculdade de Medicina, 
Universidade de Lisboa, Portugal (H Cortez-Pinto MD); Hospital Clinic de Barcelona, Barcelona, Spain (I 
Graupera MD); Auckland City Hospital, Auckland, New Zealand (D Orr MD); Copenhagen University 
Hospital Hvidovre, Hvidovre, Denmark (L Gluud MD); University Clinic for Visceral Surgery and Medicine, 
Inselspital, University of Bern, Bern, Switzerland (J F Dufour MD); Intercept Pharmaceuticals, San Diego, 
CA, USA (D Shapiro MD, J Campagna MD, L Zaru PhD, L MacConell PhD, R Shringarpure MD); Pinnacle 
Clinical Research Center, San Antonio, TX, USA (S Harrison MD); Virginia Commonwealth University, 
Richmond, VA, USA (Prof A J Sanyal MD) 
 
*Equal contribution as first author. 
†Equal contribution as senior author. 
 
Correspondence to: 
Prof Arun J Sanyal, MD 
Department of Internal Medicine 
Division of Gastroenterology, Hepatology and Nutrition 
Virginia Commonwealth University 
1250 E. Marshall St, Richmond, VA 23298, USA 
Phone: 804-828-4060, E-mail: arun.sanyal@vcuhealth.org 
  
2 
 
SUMMARY 
Background: Nonalcoholic steatohepatitis (NASH) is a common type of chronic liver disease 
that can lead to cirrhosis. Obeticholic acid (OCA), a farnesoid X receptor agonist, has been 
shown to improve the histologic features of NASH. Results of a planned interim analysis of an 
ongoing, multicentre, randomised, double-blind, placebo-controlled phase 3 study of OCA for 
NASH are reported. 
Methods: Patients with definite NASH, nonalcoholic fatty liver disease (NAFLD) activity score 
≥4 and fibrosis stages F2–F3, and an exploratory cohort (fibrosis stage F1), were randomised to 
receive placebo, OCA 10-mg, or OCA 25-mg daily in a 1:1:1 ratio. The primary endpoints for 
the month 18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of 
NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful 
if either primary endpoint was met. The study also evaluated other histologic and biochemical 
markers of NASH and fibrosis, and safety (NCT02548351; EudraCT 2015-002560-16). 
Findings: The intent-to-treat population included 931 patients with stage F2–F3 fibrosis 
(placebo, n=311; OCA 10-mg, n=312; OCA 25-mg, n=308). The fibrosis improvement endpoint 
was achieved by 12% of placebo patients, 18% of OCA 10-mg patients, and 23% of OCA 25-mg 
patients (p=0·0002). Although the NASH resolution endpoint was not met (placebo, 8%; OCA 
10-mg, 11%; OCA 25-mg, 12%), more OCA 25-mg patients achieved resolution of definite 
NASH based on pathologist’s assessment (p=0.0004). In the safety population (F1–F3, N=1968), 
the most common adverse event was pruritus (placebo, 19%; OCA 10-mg, 28%; OCA 25-mg, 
51%); incidence was generally mild to moderate in severity. The overall safety profile was 
similar to that in previous studies, and incidence of serious adverse events was similar across 
treatment groups (11–14%). 
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Interpretation: OCA 25-mg significantly improved fibrosis and key components of NASH 
disease activity among patients with NASH. 
Funding: Intercept Pharmaceuticals. 
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INTRODUCTION 
 
Nonalcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease 
characterised by hepatocellular injury, inflammation, and progressive fibrosis. Models of disease 
progression project that the overall burden of end-stage liver disease due to NASH is likely to 
increase two- to three-fold over the next two decades.1 Currently, there are no approved therapies 
for NASH. 
The farnesoid X receptor (FXR) is a nuclear receptor that plays a central role in the regulation of 
bile acids and metabolism.2 Recent data indicate that activation of FXR can also reduce hepatic 
fibrosis and inflammation.2–5 Prior placebo-controlled clinical studies demonstrated that 
obeticholic acid (OCA), a potent and selective FXR agonist, improved glucose disposal after 
short-term administration6 and key histologic features of NASH, including fibrosis.7 Based upon 
a prior phase 3 study, OCA was approved for the treatment of primary biliary cholangitis, a 
progressive autoimmune liver disease, in patients with an inadequate response to, or unable to 
tolerate, ursodeoxycholic acid.8 Collectively, this provided a strong rationale for assessing the 
efficacy and safety of OCA in patients with NASH and fibrosis in this pivotal phase 3 study. 
Liver-related outcomes in patients with NASH principally occur after the development of 
cirrhosis; halting progression to cirrhosis is therefore a key treatment goal. Given the length of 
time to progress to cirrhosis and clinical outcomes, a conditional approval pathway based on 
demonstration of histologic improvement following at least 12 months of treatment is supported 
by the US Food and Drug Administration (FDA) and the European Medicines Agency.9,10  
The RandomizEd Global phase 3 Study to Evaluate the impact on NASH with fibRosis of 
obeticholic Acid TreatmEnt (REGENERATE) study is a multi-centre, randomised, double-blind, 
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placebo-controlled phase 3 study of OCA in patients with NASH and fibrosis (NCT02548351).11 
Here, we report the results of the prespecified month 18 interim analysis on the safety and 
efficacy of OCA in improving fibrosis and underlying disease activity. 
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METHODS 
 
Study design and participants 
This study is being conducted at 332 centres in 20 countries. Eligible patients were adults (aged 
≥18 years) with histologic evidence (per central expert pathologist reading of a liver biopsy 
obtained ≤6 months from randomisation) of definite steatohepatitis; a nonalcoholic fatty liver 
disease (NAFLD) activity score (NAS) ≥4 points, including ≥1 point for each of steatosis, 
lobular inflammation, and hepatocellular ballooning; and fibrosis stage per the NASH CRN 
scoring criteria of F2 or F3, or F1 with ≥1 accompanying comorbidity (obesity, type 2 diabetes, 
or alanine amino transferase [ALT] >1·5x ULN. Patients were excluded if cirrhosis, other 
chronic liver disease, significant alcohol consumption (>2 units/day for women or >4 units/day 
for men for >3 months ≤1 year before screening), or confounding conditions were present. All 
patients provided written informed consent. The detailed study design, including inclusion and 
exclusion criteria, was previously reported11 and a summary of protocol changes can be reviewed 
on clinicaltrials.gov. 
A planned interim analysis was performed after a minimum of 750 randomised patients with 
fibrosis stages F2 or F3 reached their actual/planned month 18 visit. The end-of-study analysis 
will evaluate the effect of OCA on clinical outcomes (including progression to cirrhosis and all-
cause mortality) and the long-term safety of OCA, and will be completed once approximately 
291 adjudicated clinical outcome events occur in the combined OCA 25-mg and placebo groups 
in patients with fibrosis stage F2 or F3. Patients are expected to have a minimum follow-up time 
of approximately 4 years. 
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Randomisation and blinding 
Eligible patients were randomised in a 1:1:1 ratio to receive daily placebo, OCA 10-mg, or OCA 
25-mg orally. Randomisation was performed using an Interactive Web Response System; for 
patients with fibrosis stage F2 or F3, randomisation was stratified by both the presence of type 2 
diabetes and the use of thiazolidinediones (TZD) or vitamin E at baseline. Placebo and OCA 
were supplied as identical tablets in coded containers. All patients, study investigators, and other 
site research staff were blinded to treatment assignment. 
 
Procedures and assessments 
Biopsies were obtained at screening and month-18/end-of-treatment. Histologic assessments 
followed standardised criteria to ensure consistency, and all biopsies were read centrally. The 
month 18 (or early termination) biopsy slides were paired together with the screening biopsy 
slides and randomly assigned for reading by one of two central expert liver pathologists who was 
blinded to both the slide sequence and the patient’s treatment. Assessments of liver biochemistry 
were performed at each study visit. Safety and tolerability of OCA were assessed by analysis of 
adverse events (AEs), vital signs, electrocardiograms, and clinical laboratory assessments 
(including lipid profile changes). An independent data monitoring committee reviewed, and 
continues to review, safety during the study. 
 
Endpoints 
This study was designed to assess liver histology at month 18 as a surrogate endpoint for clinical 
outcomes.11 The primary endpoints were defined as improvement in fibrosis (reduction of ≥1 
stage) with no worsening of NASH (defined as no increase of hepatocellular ballooning, lobular 
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inflammation, or steatosis), or NASH resolution (defined as the overall histopathologic 
interpretation of “no fatty liver disease” or “fatty liver disease without steatohepatitis” and a 
NAS of 0 for ballooning and 0–1 for inflammation) with no worsening of fibrosis. The key 
secondary endpoint was improvement of fibrosis by ≥1 stage and/or resolution of NASH without 
worsening of either. Secondary endpoints also included histologic improvement of features of 
NASH as well as NAS, and liver biochemistry.11 A post-hoc analysis evaluated NASH resolution 
based on the pathologist diagnostic assessment of presence/absence of definite steatohepatitis as 
determined by the overall pattern of injury rather than scoring of individual NAS parameters.  
 
Statistical analyses 
For the month 18 primary efficacy endpoint of improvement in fibrosis with no worsening of 
NASH, a sample size of 250 per group with an assumed 15% discontinuation rate will provide 
98% power to demonstrate a statistically significant treatment difference between the OCA (10-
mg and 25-mg) and placebo groups based on the Cochran-Mantel-Haenszel (CMH) test with a 
two-sided Type I error at the 0·01 level, assuming an adjusted response rate of 36·7% and 17·6% 
in the OCA (10-mg and 25-mg) and placebo groups, respectively. The 2-sided Type I error 
(alpha) allocated to testing both histologic endpoints at the month 18 interim analysis is 0.02. 
Inferential testing was performed sequentially in the dose level, adjusting for multiplicity using a 
truncated Hochberg procedure, to test the two primary endpoints within each dose level, starting 
by comparing the OCA 25-mg group with placebo for the two primary endpoints, then 
comparing the OCA 10-mg group with placebo in the intent-to-treat (ITT) population (see 
supplemental methods). All other testing and the associated p values reported here are not 
controlled for Type I error and are considered nominal and descriptive. Success of the study was 
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defined as meeting one of the two primary endpoints at the predetermined significance level. For 
histologic endpoints, the comparison between treatment groups was performed using the CMH 
test stratified by the randomisation strata (type 2 diabetes and use of TZDs/glitazones or vitamin 
E at baseline [yes/no]). Continuous endpoints, change from baseline and percentage change from 
baseline over time were analysed using a mixed-effect repeated measure (MMRM) model with 
treatment, baseline, visit, visit by treatment interaction and stratification factors included in the 
model. The statistical analysis plan, primary endpoints, and requirement for study success were 
agreed with the FDA prior to database lock. More information can be found in the supplemental 
methods. 
As shown in figure 1, all patients (fibrosis stages F1-F3) who received ≥1 dose of study 
treatment by the pre-specified month 18 interim analysis cutoff date were included in the safety 
population, which was used for all safety and tolerability analyses. The primary analysis 
population for efficacy endpoints was the ITT population, comprised of patients with more 
advanced disease (fibrosis stage F2-F3) who had received ≥1 dose of treatment and reached, or 
would have reached, the month 18 visit by the pre-specified interim analysis cutoff date. Efficacy 
endpoints were also analysed in the per-protocol population, defined as the ITT population who 
completed ≥15 months of treatment, had a month 18/end-of-treatment biopsy, were on treatment 
≥30 days immediately preceding biopsy, and did not have any major protocol deviation. 
 
Role of the funding source 
The REGENERATE study was designed by VR, AJS, and ZMY in collaboration with Intercept 
Pharmaceuticals. Operational and protocol-specific aspects were supervised by a steering 
committee comprising AJS, MR, PB, QMA, RL, SH, VR, ZG, and ZMY (chair). All authors 
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vouch for the fidelity of the study to the protocol, the accuracy and completeness of the data, and 
approved publication of the manuscript. The first and corresponding authors had full access to 
the data in the study and had final responsibility for the decision to submit for publication. 
Funding for the study was provided by Intercept Pharmaceuticals. No funding was provided to 
any author for writing and editing of the manuscript. Any funding support the authors received 
was related to compensation for services provided outside of manuscript participation. 
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RESULTS 
Between December 2015 and October 2018, a total of 1968 patients were enrolled and randomly 
assigned to one of the three treatment groups (figure 1). The ITT population included 931 
patients randomised to receive placebo (n=311), OCA 10-mg (n=312), or OCA 25-mg (n=308). 
At the time of the interim analysis, 23% of placebo, 23% of OCA 10-mg, and 25% of OCA 25-
mg patients had discontinued treatment (figure 1); 81% of patients receiving placebo or OCA 10-
mg and 79% receiving OCA 25-mg completed the month 18 biopsy. An additional 3% of 
patients in each treatment group completed any post-baseline biopsy (patients who discontinued 
treatment before month 18 and underwent an end-of-treatment biopsy). The per-protocol 
population included 668 patients (placebo, n=224; OCA 10-mg, n=226; OCA 25-mg, n=218) and 
the safety population included 1968 patients (placebo, n=657; OCA 10-mg, n=653; OCA 25-mg, 
n=658).  
In the ITT population, baseline characteristics were balanced across treatment groups and 
reflective of a noncirrhotic NASH population (table 1). A majority of patients had stage F3 
fibrosis (54–58%) and NAS ≥6 (68–70%) indicative of advanced fibrosis and high disease 
activity. Consistent with NASH epidemiology, more than half of the patients had type 2 diabetes 
(55–56%), and 52-54% overall were receiving antidiabetic medication at baseline. Additionally, 
41–46% of patients were receiving statin therapy and a minority were receiving NASH-
modifying agents, TZD (1-3%) and vitamin E (10-14%). A similar pattern of baseline 
characteristics was observed in the per-protocol population (table S1).  
The primary endpoint of fibrosis improvement by ≥1 stage with no worsening of NASH was met 
by 12% of placebo, 18% of OCA 10-mg (p=0·04 vs placebo) and 23% of OCA 25-mg patients 
(p=0·0002 vs placebo) with an OCA:placebo response ratio (95% confidence interval [CI]) of 
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1·48(1·01, 2·18) and 1·94(1·35, 2·78) for OCA 10-mg and OCA 25-mg, respectively (figure 2, 
table 2). OCA 25-mg was statistically significant per the inferential testing method pre-specified 
in the statistical analysis plan. Similar results were observed in the per-protocol population 
(placebo 13%, OCA 10-mg 21% [p=0·02], OCA 25-mg 28% [p<0·0001]) (figure 2, table 2). 
Across subgroups of interest in the ITT population, ≥1 stage improvement in fibrosis was 
observed in the OCA 25-mg group. Several of the subgroups analyses were limited by 
imbalances in sample sizes within a given subgroup to an extent that precluded meaningful 
comparison (figure S1).  
In the per-protocol population, which includes patients with ≥15 months of treatment, three times 
as many patients in the OCA 25-mg group achieved ≥1 stage improvement in fibrosis (38%) as 
opposed to progression of fibrosis (13%) compared to the placebo group, which showed a similar 
number of patients who improved (23%) or worsened (21%) (figure 3). Based on this analysis, 
after 18 months of treatment, on a placebo-subtracted basis 4 to 5 patients with NASH and 
fibrosis F2/F3 would need to be treated with OCA 25-mg for one such patient to achieve either 
improvement (≥1 stage) or no worsening of fibrosis. 
The primary endpoint of NASH resolution (based on no hepatocellular ballooning and 
no/residual lobular inflammation) with no worsening of fibrosis did not meet statistical 
significance in the ITT population (placebo 8%, OCA 10-mg 11% [p=0·18], OCA 25-mg 12% 
[p=0·13]) with an OCA:placebo response ratio (95% CI) of 1·39(0·86, 2·25) and 1·45(0·90, 
2·35) for OCA 10-mg and OCA 25-mg, respectively (figure 2, table 2). Similar results were 
observed in the per-protocol population (figure 2, table 2). Despite not meeting the NASH 
resolution endpoint, a dose-dependent response was observed in the ITT population with more 
OCA 25-mg patients compared to placebo achieving ≥1-point improvement in scores of lobular 
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inflammation (44% vs 36%, p=0·03) and hepatocellular ballooning (35% vs 23%, p=0·001), key 
histologic features of NASH (figure S2).  
In a post-hoc analysis, NASH resolution was evaluated by assessing a change from presence of 
definite steatohepatitis at baseline to absence of definite steatohepatitis (without worsening of 
fibrosis) at month 18. This pathologist diagnostic assessment of NASH, based on the overall 
pattern of liver injury, showed that in the ITT population approximately twice as many patients 
in the OCA 25-mg group achieved NASH resolution compared with the placebo group (23% vs 
12%, p=0·0004) (figure S3). A similar dose-dependent response was observed in the per-
protocol population (29% vs 16%, p=0·0005) (figure S3). 
The key secondary endpoint of improvement of fibrosis by ≥1 stage and/or resolution of NASH, 
without worsening of either was achieved by 16% of placebo, 22% of OCA 10-mg (p=0·07) and 
27% of OCA 25-mg patients (p=0·0005) (ITT population) (table 2, figure S4). A significantly 
higher proportion of patients receiving OCA 25-mg compared to placebo achieved improvement 
in NAS by ≥2-points with no worsening of fibrosis (36% vs 24%, p=0·001); had no disease 
progression as assessed by no worsening of fibrosis and no worsening of NASH (48% vs 38%, 
p=0·011); and had improvement in fibrosis by ≥2 stages (10% vs 5%, p=0·018) (table 2). 
Additional secondary NASH and fibrosis endpoints are provided in table 2. 
Favourable changes in key liver enzymes were observed in OCA-treated patients. Early dose-
dependent decreases in ALT and aspartate aminotransferase (AST) were observed by month 3 
and continued through month 18 (mean [standard error (SE)] change at month 18 ALT: placebo 
–15·6 [3·3] U/L, OCA 10-mg –23·8 [2·6] U/L, OCA 25-mg –36·0 [3·6] U/L; AST: placebo –9·8 
[2·4] U/L, OCA 10-mg –14·1 [2·1] U/L, OCA 25-mg –20·4 [2·3] U/L) (figure 4). These changes 
correspond to a decrease in ALT of 6% for placebo, 26% for OCA 10-mg, and 33% for OCA 25-
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mg and in AST of 4%, 19%, and 24%, for placebo, OCA 10-mg, and OCA 25-mg, respectively 
(figure 4). A post-hoc analysis demonstrated that a higher proportion of patients receiving OCA 
with elevated ALT and AST at baseline achieved levels below the ULN at month 18 compared 
with placebo (figure S5). Gamma-glutamyl transferase (GGT) levels declined rapidly and were 
generally stable after month 3 (change at month 18: placebo 1%, OCA 10-mg –24%, OCA 25-
mg –38%) (figure 4). Increases in alkaline phosphatase (ALP) were observed with OCA 
treatment, but levels remained below ULN through month 18 (change at month 18: placebo –1%, 
OCA 10-mg 9%, OCA 25-mg 20%) (figure 4).  
Additionally, treatment with OCA versus placebo resulted in a dose-dependent decrease in body 
weight at month 18 (mean [SE] change: placebo, –0·7 [0·4] kg; OCA 10-mg, –1·8 [0·4] kg; OCA 
25-mg –2·2 [0·3] kg). 
A total of 1968 patients were included in the safety analysis, comprised of fibrosis stage F1 
(15%), stage F2 (35%), and stage F3 (50%). The duration of exposure was generally similar 
across treatment groups. Overall, treatment-emergent AEs occurred in 83% of placebo, 89% of 
OCA 10-mg, and 91% of OCA 25-mg patients; most (69–74%) were mild to moderate in 
severity (table 3). The frequency of serious AEs (SAEs) was similar across treatment groups 
(11–14%) and no single SAE occurred in >1% of patients in any treatment group (table 3). The 
most frequent AE was pruritus (placebo, 19%; OCA 10-mg, 28%; OCA 25-mg, 51%) (table 3). 
The incidence of pruritus was highest during the first 3 months of treatment with OCA, and 
generally mild to moderate in severity. Treatment discontinuation due to pruritus occurred in five 
placebo (<1%), five OCA 10-mg (<1%), and 57 OCA 25-mg patients (9%). Of those 57 patients 
in the OCA 25-mg group who discontinued due to pruritus, 36 discontinuations were protocol-
mandated based on the investigator-assessed grade of the event.  
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In patients receiving OCA, low-density lipoprotein cholesterol (LDLc) increased by month 1 
(mean [SE]: placebo –3·0 [0·9] mg/dL, OCA 10-mg, 17·8 [1·0] mg/dL, OCA 25-mg 23·8 [1·1] 
mg/dL) and decreased thereafter, approaching baseline by month 18 (mean [SE]: placebo –
7·1[1·7] mg/dL, OCA 10-mg, 1·4 [2·0] mg/dL, OCA 25-mg 2·7 [2·1] mg/dL) (figure 5). A total 
of 380 patients started statin therapy during the study (placebo, n=66; OCA 10-mg, n=155; OCA 
25-mg, n=159). Among OCA-treated patients who initiated statins, the initial LDLc increases 
reversed to below baseline levels as of month 6 and were sustained through month 18 (figure 
S6). There was no clear pattern of fibrosis improvement by statin use. Levels of high-density 
lipoprotein cholesterol (HDLc) showed dose-dependent decreases by month 1 (mean [SE]: 
placebo –0·7 [0·2] mg/dL, OCA 10-mg, –1·8 [0·2] mg/dL, OCA 25-mg –4·6 [0·3] mg/dL) and 
were sustained through month 18; mean HDLc remained within the normal limit (>40 mg/dL) at 
all timepoints. Changes in total cholesterol over time were similar to LDLc. A dose-dependent 
decrease in triglycerides was observed by month 1 in the OCA groups, with levels continuing to 
decline with a maximum mean change from baseline of –37·4 mg/dL in the OCA 25-mg group at 
month 18 (figure 5).  
The incidence of cardiovascular AEs and SAEs was similar across treatment groups (AEs: 5% 
placebo, 7% OCA 10-mg, and 6% OCA 25-mg; SAEs 2% placebo, 1% OCA 10-mg, 2% OCA 
25-mg).  Effects on glycemic parameters were evaluated by baseline diabetes status (figure S7). 
In patients with type 2 diabetes, OCA treatment was associated with an early transient increase in 
glucose and HbA1C with return to levels similar to placebo by month 6. No clinically 
meaningful changes were noted in nondiabetic patients. Blood pressure was generally stable, but 
variable, with no significant difference between treatment groups. Other vital signs were not 
affected by study treatments.  
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Gallstone-related AEs occurred at a rate of <1%, 1% and 3% in placebo, OCA 10-mg and OCA 
25-mg patients respectively. Pancreatitis, a more serious and potentially gallstone-related event, 
was rare and evenly distributed across treatment groups (incidence <1%). Hepatic SAEs were 
uncommon, and each case was reviewed by independent expert hepatologists. While more events 
occurred in the OCA 25-mg group (0·9%) than the OCA 10-mg group (0·3%) or placebo group 
(0·3%), expert reviewers did not identify any consistent pattern of liver injury and all cases were 
associated with confounding concomitant medications and/or severe intercurrent illness.  
A total of three deaths occurred on study (two placebo [bone cancer and cardiac arrest], and one 
OCA 25-mg [glioblastoma]); none were considered related to study treatment.  
 
DISCUSSION 
 
This  study is the first positive phase 3 trial in NASH and represents a landmark in the 
development of new therapies for an increasingly common chronic liver disease.12–15 Treatment 
with OCA 25-mg met the primary endpoint of improvement in fibrosis with no worsening of 
NASH in patients with stage F2 or F3 fibrosis, at the month 18 interim analysis. The robust 
antifibrotic effect of OCA was dose-dependent and consistent across different patient 
populations, subgroups, and was further supported by fibrosis-related secondary endpoints 
including a ≥2-stage improvement in fibrosis. Per the draft guidance from the FDA on efficacy 
endpoints for clinical trials in NASH, improvement in fibrosis by ≥1 stage with no worsening of 
NASH is reasonably likely to predict clinical benefit.10 Patients with NASH have an almost 65 
times greater risk of liver-specific mortality and almost 3 times greater risk/rate of overall 
mortality compared to healthy subjects.14 Fibrosis has been shown to be the strongest histologic 
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predictor of liver-related adverse outcomes, including liver-related death.16–19 Treatment with 
OCA 25-mg both improved fibrosis and prevented progression of fibrotic disease, demonstrating 
a halting of disease progression. To slow or reverse the progression of fibrosis is the ultimate 
goal of NASH treatment as fibrosis is the most reliable predictor of liver-related mortality and 
once patients progress to cirrhosis, preventing complications of cirrhosis may become even more 
difficult.16,18  
Although the percentage of patients achieving NASH resolution was not statistically significant 
between OCA and placebo, more patients receiving OCA 25-mg showed improvements in 
hepatocellular ballooning and lobular inflammation, the two key individual histologic features of 
the pre-specified NASH resolution endpoint. These data are relevant given that features of 
steatohepatitis, such as hepatocellular ballooning, are predictive of increased liver-related events 
and reduced liver transplant-free survival.19 In addition, more patients receiving OCA 25-mg had 
a ≥2-point improvement in NAS with no worsening of fibrosis, the primary endpoint 
traditionally used in phase 2 studies such as FLINT7 and PIVENS,20 indicating that OCA reduces 
NASH disease activity.  
Twice as many OCA 25-mg patients compared to placebo achieved NASH resolution as 
determined by the pathologist diagnostic assessment of the absence of definite steatohepatitis at 
month 18. This evaluation was based on an assessment of the overall pattern of histologic lesions 
or injury, as opposed to the more rigid categorical scoring system of the pre-specified 
methodology described above. This finding has clinical relevance given that this definition is 
commonly used to diagnose NASH in clinical practice, as well as in natural history studies 
evaluating the correlation of definite NASH and mortality16. T The assessment of NASH 
resolution based on NAS parameters appears to be more rigid and may be associated with greater 
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intra- and inter-rater variability compared to the diagnostic classification of NASH.21 The NAS, 
a tool designed to measure disease activity and severity in NASH, is distinct from a clinical 
diagnosis of definite steatohepatitis. In an investigation into the relationship between NAS and 
the diagnosis of steatohepatitis, threshold values of NAS did not always correlate with 
pathologist overall assessment of presence of NASH.22 Therefore, as the field continues to 
evolve it may be more appropriate to establish the presence/absence of NASH using histologic 
diagnostic criteria as an endpoint as has been done by NIDDK’s NASH CRN in the past. 
In addition to consistent improvements in multiple histologic parameters, improvement in liver 
health was also evident based on clinically meaningful, dose-dependent, improvements in 
markers of liver injury (ALT and AST) and oxidative stress (GGT). The modest increases in 
ALP are consistent with earlier observations and are associated with an on-target effect of FXR 
activation. 
Lifestyle modifications including weight loss have been shown to be an effective 
nonpharmacologic therapy for NAFLD. Weight loss >7% has been associated with improvement 
in NAS, and weight loss ≥10% has been associated with improvement in fibrosis.23 OCA-treated 
patients experienced weight loss of approximately 2%, an amount lower than that expected to 
have an effect on histologic parameters of NASH. Although modest, the effect of OCA on 
weight is important to note given the prevalence of obesity and metabolic abnormalities in this 
population.  
Based on a substantial safety population including almost 2000 patients, of whom approximately 
900 were exposed for ≥18 months, OCA was generally well tolerated. The majority of AEs were 
mild to moderate in severity and were generally consistent with the known safety profile of 
OCA.7 As previously seen, mild to moderate pruritus was the most commonly reported AE, with 
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dose-dependent incidence. More patients in the OCA 25-mg group experienced pruritus that led 
to treatment discontinuation; however, the majority of randomised patients were ongoing in the 
study through at least month 18 and the overall treatment discontinuation rate was similar to 
placebo. The impact of pruritus in this study on patient-reported outcomes and its relationship to 
OCA is being investigated.24 The incidence of hepatic AEs was balanced across treatment 
groups, and serious hepatic events were rare; although numerically more occurred in the OCA 
25-mg treated group, there was no clear pathologic pattern seen consistently among these SAEs 
and all cases were confounded by concomitant medications and/or severe intercurrent illness. 
Treatment with OCA was associated with serum lipid changes that were consistent with a class 
effect of FXR activation, as well as limited and generally transient increases in glycemic 
parameters. Such increases were manageable by clinical practice measures. The impact of lipid 
changes on cardiovascular risk should be assessed in the context of other OCA-related reductions 
in risk factors, including a decrease in weight, serum triglyceride levels, and GGT, a promising 
marker for assessing cardiovascular risk, as well as improvements in liver fibrosis, which may 
have a downstream effect on cardiovascular risk.19,25-27 The incidence of cardiovascular AEs and 
SAEs was low and similar across treatment groups and continues to be monitored in the 
outcomes portion of the study.  
The results of the interim analysis reported here are clinically relevant in the context of fibrosis 
due to NASH but may underestimate the long-term benefit of OCA on the target illness. 
Improvement in fibrosis, a generally slow process, was observed at the month 18 interim analysis 
of the ongoing study, and the effect size may increase with prolonged therapy. This has been 
shown with other interventions that reported improvement in fibrosis at early time points with a 
greater effect over the longer term. For example, tenofovir treatment resulted in 10% fewer 
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patients with hepatitis B virus-associated advanced fibrosis or cirrhosis after the first year of 
treatment (28% vs 38% at baseline).28 In the tenofovir study, patients continued to improve on 
treatment, and the proportion of patients with advanced fibrosis or cirrhosis declined to 12% at 
year 5.27 In REGENERATE, the continuing improvement in liver enzyme markers of fibrosis 
such as ALT and AST suggest the potential for further increase in antifibrotic response. Data 
from the ongoing long-term outcomes portion of the study will inform whether prolonged 
therapy will result in a greater antifibrotic benefit. 
In conclusion, the totality of data from the month 18 interim analysis of this pivotal, phase 3 
study provides strong evidence that OCA treatment improves clinically significant histologic 
endpoints deemed reasonably likely to predict clinical benefit and affirms the positive benefit-
risk of OCA for the treatment of NASH with fibrosis. Beneficial effects of OCA on fibrosis and 
key components of NASH disease activity were robust, based on the observed consistency of 
results across multiple histologic endpoints with reproducible response ratios, as well as the 
evident dose-response and markedly consistent benefit across analysis populations. Treatment 
with OCA had a beneficial effect on other markers of hepatocellular injury (ALT and AST), and 
oxidative stress (GGT). OCA was generally well tolerated, with a profile that is generally 
consistent with prior studies. Following the month 18 interim analysis, this study  continues in a 
blinded fashion, and patients will be followed over an extended period through clinical outcomes 
(including all-cause mortality and liver-related clinical outcomes) and long-term safety, to 
confirm clinical benefit. In a chronic liver disease with no approved therapies and potential for 
serious sequelae, these findings provide compelling evidence that patients with non-cirrhotic 
advanced fibrosis due to NASH may benefit from OCA treatment.   
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FIGURE LEGENDS 
Figure 1. Patient flow diagram. *750 patients included in the safety population had not reached 
their M18/EOT visit by DCO and were therefore not included in the ITT or per-protocol 
populations. AE=adverse event, DCO=data cutoff, EOT=end-of-treatment; ITT=intent-to-treat, 
M18=month 18, OCA=obeticholic acid. 
Figure 2. Primary endpoints. The proportion of patients with improvement in fibrosis ≥1 stage 
and no worsening of NASH in the ITT (Panel A) and per-protocol (Panel B) populations, and the 
proportion of patients with resolution of NASH and no worsening of fibrosis in the ITT (Panel 
C) and per-protocol (Panel D) populations. Fibrosis improvement was evaluated per NASH CRN 
criteria; no worsening of NASH defined as no worsening of hepatocellular ballooning, lobular 
inflammation or steatosis. NASH resolution defined as: (i) overall pathologist assessment of “no 
steatohepatitis,” and (ii) hepatocellular ballooning = 0 and lobular inflammation = 0 or 1. 
*Statistically significant in accordance with the statistical analysis plan as agreed with the FDA. 
FDA=US Food and Drug Administration; ITT=intent to treat; NASH=nonalcoholic 
steatohepatitis; OCA=obeticholic acid. 
Figure 3. Regression or progression of fibrosis by ≥1 stage. The proportion of patients with 
improved or worsened fibrosis by ≥1 stage is shown for patients in the per-protocol population 
with available fibrosis stage data at month 18/end of treatment (n=656). OCA=obeticholic acid. 
Figure 4. Changes in liver biochemistry over time. Mean (SE) values of change from baseline up 
to month 18 are shown for patients from each treatment group in the ITT population (○ placebo, 
▲ OCA 10-mg, ▼ OCA 25-mg). ALP=alkaline phosphatase; ALT=alanine aminotransferase; 
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AST, aspartate aminotransferase; GGT=gamma-glutamyl transferase; ITT=intent to treat; 
OCA=obeticholic acid; SE=standard error. 
Figure 5. Changes in serum lipids over time. Mean (SE) values of change from baseline up to 
month 18 are shown for patients from each treatment group in the safety population (○ placebo, 
▲ OCA 10-mg, ▼ OCA 25-mg). HDLc=high-density lipoprotein cholesterol; LDLc=low-
density lipoprotein cholesterol; OCA=obeticholic acid; SE=standard error. 
